Trial Profile
A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder with Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 17 Oct 2021 Results of a pooled gender-focused analysis assessing long-term safety effects of onabotulinumtoxin A from following clinical studies: NCT00910845, NCT00910520, NCT01767519, NCT01945489 and NCT00915525 presented at the 51st Annual Meeting of the International Continence Society
- 10 May 2016 Results assessing long term effects of onabotulinumtoxinA on HRQoL presented at the 111th Annual Meeting of the American Urological Association.
- 30 Mar 2016 Extension study results published in the Journal of Urology